Full-Time

Contract – Manufacturing Associate

Posted on 1/10/2025

Vedanta Biosciences

Vedanta Biosciences

51-200 employees

Develops microbiome-based therapies using bacteria

Biotechnology
Healthcare

Junior, Mid

Cambridge, MA, USA

Occasional travel to Vedanta’s Acton, MA manufacturing facility may be required.

Category
Bioinformatics
Biology Lab & Research
Biology & Biotech

You match the following Vedanta Biosciences's candidate preferences

Employers are more likely to interview you if you match these preferences:

Degree
Experience
Requirements
  • BS in a Scientific Discipline or Engineering
  • 2+ years of hands-on experience with CGMP manufacturing
  • Direct experience with cell banking, cell culture, fermentation, cross-flow filtration, lyophilization, and/or capsule filling
  • Ability to work in a fast-paced setting and adjust to a changing environment
  • Excellent interpersonal and communication skills
  • Ability to work in a team setting
Responsibilities
  • Manufacture Master Cell Banks, Drug Substance and Drug Product in a CGMP environment
  • Prepare process solutions including media and buffer
  • Request materials and supplies from Supply Chain/QC/QA to support manufacturing activities
  • Maintain the in-suite consumable inventory
  • Operate and maintain small-scale process equipment
  • Author and revise SOPs

Vedanta Biosciences focuses on developing microbiome therapies using groups of beneficial bacteria known as bacterial consortia. These consortia can colonize the human intestine and have the potential to treat various diseases. The company utilizes a proprietary discovery platform to identify and assemble these bacteria into effective therapeutic teams. Unlike many competitors, Vedanta has achieved commercial-scale production of its drug candidates while adhering to strict FDA regulations for safety and quality. The goal of Vedanta Biosciences is to transform disease treatment by providing new options for patients through its innovative approach to drug discovery.

Company Stage

Late Stage VC

Total Funding

$364.5M

Headquarters

Cambridge, Massachusetts

Founded

2010

Growth & Insights
Headcount

6 month growth

-2%

1 year growth

0%

2 year growth

-1%
Simplify Jobs

Simplify's Take

What believers are saying

  • Fast Track designation for VE303 accelerates regulatory approval process.
  • Phase 3 RESTORATiVE303 study positions Vedanta as a market leader for rCDI.
  • Recent $106.5M funding round strengthens financial position and growth potential.

What critics are saying

  • Competition from Seres Therapeutics with FDA-approved C. difficile treatment.
  • High production costs may impact profitability and market reach.
  • Regulatory challenges due to unclear FDA guidelines for microbiome therapies.

What makes Vedanta Biosciences unique

  • Vedanta uses defined bacterial consortia for consistent therapeutic outcomes.
  • First to achieve commercial-scale CGMP production of bacterial consortia drugs.
  • Proprietary platform identifies and assembles optimal bacterial consortia for therapies.

Help us improve and share your feedback! Did you find this helpful?

INACTIVE